Publication

Discriminating among degenerative parkinsonisms using advanced 123I-ioflupane SPECT analyses

Related publications (34)

About
Privacy
Disclaimer

Graph Chatbot

Chat with Graph Search

Ask any question about EPFL courses, lectures, exercises, research, news, etc. or try the example questions below.

DISCLAIMER: The Graph Chatbot is not programmed to provide explicit or categorical answers to your questions. Rather, it transforms your questions into API requests that are distributed across the various IT services officially administered by EPFL. Its purpose is solely to collect and recommend relevant references to content that you can explore to help you answer your questions.

Discriminating among degenerative parkinsonisms using advanced 123I-ioflupane SPECT analyses

Graph Chatbot

Chat with Graph Search

Development and clinical validation of computational imaging biomarkers for neurodegenerative diseases

Tau seeds from patients induce progressive supranuclear palsy pathology and symptoms in primates

Capturing the heterogeneity of alpha-synuclein pathology in synucleinopathies

Alpha-synuclein as a Potential Biomarker for Parkinson’s Disease and Other Synucleinopathies: Gaps, Challenges, and Opportunities

Opportunities and challenges of alpha-synuclein as a potential biomarker for Parkinson's disease and other synucleinopathies

Fading of brain network fingerprint in Parkinson's disease predicts motor clinical impairment

Do Lewy bodies contain alpha-synuclein fibrils? and Does it matter? A brief history and critical analysis of recent reports

A method for fast automated assessment of the magnetic resonance parkinsonism index

Discovery of 2-(4-(2-fluoroethoxy)piperidin-1-yl)-9-methyl-9H-pyrrolo[2,3-b:4,5-c']dipyridine ([18F]PI-2014) as PET tracer for the detection of pathological aggregated tau in Alzheimer's disease and other tauopathies

Reach-to-grasp motions: Towards a dynamic classification approach for upper-limp prosthesis